SYNPO2

Across TCGA pan-cancer cohorts, SYNPO2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SYNPO2 data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SYNPO2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SYNPO2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where SYNPO2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.556	0.261	.001	71	view →
CCRCC	OS	Tertile	IV	0.198	0.830	.024	12	view →
LUAD	DFS	Quartile	II,III,IV	0.629	0.988	.009	4	view →
GBM	OS	Quartile	All	0.764	0.901	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SYNPO2–PDAC (DFS)

Open the PDAC breakdown →